Cancer and Baclofen


Cancer Symptoms and Causes

Cancer begins in your cells, which are the building blocks of your body. Normally, your body forms new cells as you need them, replacing old cells that die. Sometimes this process goes wrong. New cells grow even when you don't need them, and old cells don't die when they should. These extra cells can form a mass called a tumor. Tumors can be benign or malignant. Benign tumors aren't Cancer while malignant ones are. Cells from malignant tumors can invade nearby tissues. They can also break away and spread to other parts of the body.

Cancer is not just one disease but many diseases. There are more than 100 different types of Cancer. Most Cancers are named for where they start. For example, lung Cancer starts in the lung, and breast Cancer starts in the breast. The spread of Cancer from one part of the body to another is called metastasis. Symptoms and treatment depend on the Cancer type and how advanced it is. Most treatment plans may include surgery, radiation and/or chemotherapy. Some may involve hormone therapy, immunotherapy or other types of biologic therapy, or stem cell transplantation.

NIH: National Cancer Institute

Check out the latest treatments for cancer

cancer treatment research studies

Baclofen clinical trials, surveys and public health registries

Find Drug Side Effect reports

Baclofen Side Effects

Overdose (180)
Coma (125)
Muscle Spasticity (122)
Pain (99)
Confusional State (96)
Muscle Spasms (94)
Convulsion (92)
Completed Suicide (92)
Fatigue (82)
Fall (77)
Somnolence (76)
Pyrexia (75)
Nausea (73)
Hypertension (73)
Dizziness (72)
Headache (70)
Death (70)
Vomiting (69)
Mental Status Changes (68)
Poisoning (68)
Pneumonia (66)
Hypotension (65)
Delirium (63)
Asthenia (62)
Bradycardia (62)
Neurotoxicity (62)
Agitation (60)
Urinary Tract Infection (59)
Dyspnoea (58)
Loss Of Consciousness (55)
Condition Aggravated (54)
Cardiac Arrest (52)
Intentional Overdose (51)
Hypotonia (49)
Implant Site Effusion (48)
Gait Disturbance (47)
Malaise (47)
Depressed Level Of Consciousness (46)
Multiple Sclerosis Relapse (45)
Respiratory Arrest (45)
Withdrawal Syndrome (45)
Medical Device Complication (44)
Hallucination (43)
Tremor (43)
Pain In Extremity (42)
Suicide Attempt (42)
Respiratory Failure (42)
Disorientation (40)
Muscular Weakness (39)
Toxicity To Various Agents (39)

➢ More

Common Meds

Abilify (10132)
Adderall (1304)
Amlodipine (6664)
Amoxicillin (4387)
Benadryl (1568)
Celebrex (12876 )
Celexa (1342)
Cialis (2975)
Cipro (8580)
Citalopram (7792)
Crestor (18839)
Cymbalta (14373)
Doxycycline (1757)
Effexor (7289)
Flexeril (435)
Flomax (2177)
Fluoxetine (4261)
Gabapentin (4593)
Hydrocodone (2469)
Ibuprofen (8222)
Lantus (10968)
Lexapro (3499)
Lipitor (17769)
Lisinopril (8919)
Lyrica (27148)
Medrol (650)
Mirena (41254)
Mobic (957)
Morphine (5356)
Naproxen (538)
Neurontin (6501)
Oxycodone (4438)
Pradaxa (13372)
Prednisone (5926)
Prilosec (2631)
Prozac (1954)
Seroquel (27216)
Simvastatin (8348)
Synthroid (4452)
Tamiflu (5585)
Topamax (3748)
Tramadol (5054)
Trazodone (1458)
Viagra (5394)
Vicodin (1153)
Wellbutrin (6324)
Xanax (2847)
Zocor (5718)

Recent Reviews

Alopecia areata

Husbnd is a 15 yr. stroke survivor who had a baclofen pump since about 2001. It was replaced Nov. 2009 and nothing but trouble... passing out, weakness, falling, etc. 4 ER trips and not one dr. ever mentioned b

I am a <b>Cancer patient with Diabetes Type 2 and dependent on Human Insulin for many years. I am on Insulin on two times a day. I was on chemotherapy several times and many cycles. My sugar level is still unconrolled.&n

I had a devastating experience with this drug. I had been using Flexeril for back and neck pain but found it no longer as effective. I asked my doctor if there was something stronger. He prescribed Baclofen. Having not read the label carefully, m

I have experience hads spasm,diziness,headaches,shallow or hard breathing,slepiness,pain in the side (new)

I think i have ovarian or vaginal cancer, my nan has had it and two of my cousins have had cells removed all at young ages i am 21 years old and have had lower abdomen pains for about a year i ignored them at first but they are getting to the point w

I too had a nasty bite from baclofen.I had a craving for alcohol and was on 10 mg TID.I took 90mg at once. within one hour I feel like i was on shrooms! Very vivid CEVs(closed eyed visuals) and some ope eyed visuals(OEVs).Actually I enjoyed this.But

I was diagnosed with breast cancer grade 3 and it had,nt travelled to my lymph noeds although there was a lymph node inside my tumor as i was told this was rare i am on tamoxifen and it has been 18 months since i was first diagnosed had lump removed

In the Spring of 2008 I went to my PCP for allergy symptoms, and when he felt my neck glands to make sure that I didn't have something similiar to strept throat, he said that's the biggest Thyrioid I've ever felt, well 2 weeks later the surgeon was r

Just was looking around and saw your post. We experienced a very similar situation with our child. Was the pump just installed?

<strong>I was put on Metoprolol ER 2 years ago after having cancer. I was </strong><span style='text-decoration: underline;'>tired all day could not sleep at night, had anxiety attacks, co

1 day off the start of week 3 from day one my dreams have been crazy intense colourful wonderuss things, not stopped smoking yet although i'm not enjoying the dreaded cancer sticks....................... joking aside i have this careless attitude

4 years old boy ,liver cancer ,liver transplant . Is going to start Sorafenib . Is there any kids that got this treatment ?

52years old went on kliovance 1mg, felt great on the tables no hot flushes no weight gain feeling pretty good.Now 53 l have lung cancer dont know if it is related or not,l have never smoked in my life.l had the cancer remove and hope for the best.but

A friend of mine has cancer and the doctors are talking about having surgery and removing the sciatica nerve. My question is will he be a function with this removal.

Afer five years of Famera treatment for breast cancer, I was anticipating feeling so much better. Now diagnosed with CFS and Fibromyalgia my doctor is trying to treat me lately with Chronic Behavorial Therapy. Yesterday my daughter took me to another

After taking raptiva for about 1.5 years i developed pancreatic cancer. Half of my pancreas and all of my spleen was removed as a result I now have dibetes

Age 58, stage 1 breast cancer a year ago. double mastecomy, by choice. chemo...started aromasin in October 2008. had a bone denstity test in September 2008 and started fosamax.... had another bone denstity test in April 2009 and before the results

Am almost 60. Breast cancer survivor of 9 yrs. Taking Evista several years with no problems till Dec. 2010 . Now it's mid-March 2011. Severe shoulder pain, right shoulder. Tried stopping meds for one week. Resumed and pain increased within 7 hours. H

Am wondering does anyone know if gliclazide causes pancreatic cancer andis it dangerous to useif you have had pancreatitis in the past.

Cancer Clinical Trials and Studies

Treatments might be new drugs or new combinations of drugs, new surgical procedures or devices, or new ways to use existing treatments. The goal of clinical trials is to determine if a new test or treatment works and is safe. Clinical trials can also look at other aspects of care, such as improving the quality of life for people with chronic illnesses. People participate in clinical trials for a variety of reasons. Healthy volunteers say they participate to help others and to contribute to moving science forward. Participants with an illness or disease also participate to help others, but also to possibly receive the newest treatment and to have the additional care and attention from the clinical trial staff.
Rank Status Study
1 Not yet recruiting SGI-110 in Combination With an Allogeneic Colon Cancer Cell Vaccine (GVAX) and Cyclophosphamide (CY) in Metastatic Colorectal Cancer (mCRC)
Condition: Metastatic Colorectal Cancer
Interventions: Drug: CY;   Biological: GVAX;   Drug: SGI-110
Outcome Measures: Difference in CD45RO+ tumor infiltrating lymphocytes (TILs) measured by immunohistochemistry in pre and post-treatment tumor biopsies from patients with metastatic colorectal Cancer;   Number of Participants with Adverse Events as a Measure of Safety and Tolerability;   Overall Survival (OS);   Time To Progression (TTP);   Progression Free Survival (PFS)
2 Recruiting Genomic Testing for Primary Breast Cancer
Condition: Breast Cancer
Interventions: Procedure: Tumor Biopsy;   Other: Breast Cancer Registry
Outcome Measure: Feasibility Analysis of Genomic Predictor from Localized Invasive Breast Cancer Tumor Registry
3 Recruiting Spray Cryotherapy for Esophageal Cancer (ICE-Cancer)
Condition: Esophageal Cancer
Intervention: Device: Liquid nitrogen spray cryotherapy with the truFreeze device
Outcome Measures: Determining the response rate to therapy;   Determine disease-free survival at 12 and 36 months after treatment;   Determine the Cancer recurrence rate at 12 and 36 months after treatment;   Estimate overall survival;   Estimate progression-free survival in those who do not achieve complete pathologic response;   Determine number of treatment sessions needed for complete response in subjects in whom the primary endpoint is attained;;   Assess the safety of spray cryotherapy in this setting;
4 Recruiting Specimen and Data Study for Ovarian Cancer Early Detection and Prevention
Conditions: Cervical Cancer;   Endometrial Cancer;   Fallopian Tube Cancer;   Hereditary Breast/Ovarian Cancer (brca1, brca2);   Ovarian Cancer;   Sarcoma;   Uterine Leiomyomata;   Vaginal Cancer;   Vulvar Cancer
Interventions: Other: laboratory biomarker analysis;   Other: screening questionnaire administration;   Procedure: study of high risk factors
Outcome Measures: Identification and development of highly sensitive and specific tumor markers for the detection and management of ovarian Cancer and other gynecological malignancies;   Identification of new prevention approaches and therapies;   Identification of measures to improve the quality of life for women at increased risk for developing the disease and for women diagnosed with ovarian Cancer
5 Unknown  Early Detection of Cancers in Low Resource Countries
Conditions: Breast Neoplasms;   Uterine Cervical Neoplasms;   Ovarian Neoplasms;   Endometrial Neoplasms
Interventions: Procedure: Breast Cancer Screening and Diagnosis;   Procedure: Cervical Cancer Screening and Diagnosis;   Procedure: Ovarian Cancer Screening and Diagnosis;   Procedure: Endometrial Cancer Screening and Diagnosis
Outcome Measures: The Effectiveness of an Innovative, Low-Cost Screening and Diagnostic Methodology;   Effectiveness of CBE and Ultrasonography for Breast Cancer Detection
6 Recruiting Hypodontia and Ovarian Cancer
Conditions: Ovarian Cancer;   Hypodontia;   Breast Cancer;   Colon Cancer
Outcome Measures: Prevalence rates of hypodontia in women with ovarian Cancer;   Genetic causes for hypodontia and ovarian Cancer;   Prevalence rates of hypodontia in patients with a known risk for epithelial Cancer
7 Recruiting Tumor Genomic Profiling in Patients Evaluated for Targeted Cancer Therapy
Conditions: Solid Tumors;   Hematologic Cancers
Intervention: Other: molecular profiling of tumors
Outcome Measures: frequency of "actionable" oncogenic mutations;   To determine the impact of molecular profiling results performed in the CLIA-setting on the treatment of patients.;   interrogate the mechanisms;   To explore the genetic mechanisms of tumorigenesis
8 Recruiting Pilot Study of Allogeneic Tumor Cell Vaccine With Metronomic Oral Cyclophosphamide and Celecoxib in Patients Undergoing Resection of Lung and Esophageal Cancers, Thymic Neoplasms, and Malignant Pleural Mesotheliomas
Conditions: Lung Cancer;   Esophageal Cancer;   Malignant Pleural Mesothelioma;   Sarcoma;   Thymic Carcinoma
Interventions: Biological: Allogeneic Tumor Cell Vaccine (K562);   Drug: Celecoxib;   Drug: cyclophosphamide
Outcome Measures: Tabulation of toxicity type and grade;   To ascertain if K526-GM vaccines induce immunity to CT antigens commonly expressed in thoracic malignancies.;   To determine if metronomic oral CP and celecoxib reduce the number, percentage and function of CD4+ CD25+ Fox P3+ regulatory T cells (T reg) in peripheral blood of thoracic oncology patients.
9 Recruiting Accountability for Cancer Care Through Undoing Racism and Equity
Conditions: Breast Cancer;   Lung Cancer
Interventions: Other: ACCURE Navigator;   Other: Usual Care by Cancer Center Care Team
Outcome Measures: Lung Cancer - Lung Resection Surgery within 4 months of diagnosis Breast Cancer - Completion of surgery, radiation if surgery is breast conserving, and adjuvant chemotherapy (when indicated) within 6 months of diagnosis;   Adherence to scheduled appointments
10 Unknown  Collecting Information From Patients and Family Members With Hereditary Colorectal Cancer Syndromes or Who Are at High Risk of Developing Colorectal Cancer
Conditions: Colorectal Cancer;   Hereditary Nonpolyposis Colorectal Cancer;   PreCancerous Condition
Interventions: Other: study of socioeconomic and demographic variables;   Procedure: evaluation of Cancer risk factors;   Procedure: study of high risk factors
Outcome Measures: Identification of patients at high risk of developing hereditary colorectal Cancer;   Establishment of a tissue and data repository
11 Recruiting Dovitinib Lactate, Gemcitabine Hydrochloride, and Capecitabine in Treating Patients With Advanced or Metastatic Solid Tumors, Pancreatic Cancer and Biliary Cancers
Conditions: Adenocarcinoma of the Pancreas;   Stage III Pancreatic Cancer;   Stage IV Pancreatic Cancer;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: dovitinib lactate;   Drug: gemcitabine hydrochloride;   Drug: capecitabine;   Other: laboratory biomarker analysis;   Other: enzyme-linked immunosorbent assay;   Other: pharmacological study
Outcome Measures: Maximum tolerated dose (MTD) is defined as the highest dose level at which less than 33% of patients experience study treatment-related dose limiting toxicities (DLT);   Overall safety profile characterized by type, frequency, severity (according to National Cancer Institute [NCI] CTCAE version 4.0), timing, seriousness and relationship to study treatment;   Plasma pharmacokinetic parameters of dovitinib lactate, gemcitabine hydrochloride, capecitabine and their metabolites;   Solid tumor/dose-finding cohort: response rate, progression free survival;   Pancreas Cancer cohort: survival, response rate and progression free survival;   Pharmacodynamic effects of dovitinib lactate and Gem-Cap combination on vascular endothelial growth factor receptor (VEGFR) and fibroblast growth factor receptors (FGFR) dynamics in serum and tumor specimens
12 Recruiting Study of Carfilzomib With Irinotecan in Irinotecan-Sensitive Malignancies and Small Cell Lung Cancer Patients
Conditions: Small Cell Lung Carcinoma;   Non Small Cell Lung Carcinoma;   Irinotecan Sensitive Cancers
Interventions: Drug: Carfilzomib;   Drug: Irinotecan
Outcome Measures: Phase 1b: Determine maximum tolerated dose of Carfilzomib in combination with Irinotecan in subjects with relapsed small and non-small cell lung Cancer or other irinotecan-sensitive Cancers.;   Phase II: Assess 6 month survival of relapsed small cell lung Cancer patients treated with Carfilzomib in combination with irinotecan.;   Response rate;   Progression-free survival;   Safety/tolerability and the rates of specific adverse events;   Biomarker endpoint
13 Recruiting Comprehensive Gene Sequencing in Guiding Treatment Recommendations Patients With Metastatic or Recurrent Solid Tumors
Conditions: Recurrent Breast Cancer;   Recurrent Colon Cancer;   Recurrent Rectal Cancer;   Stage IV Breast Cancer;   Stage IVA Colon Cancer;   Stage IVA Rectal Cancer;   Stage IVB Colon Cancer;   Stage IVB Rectal Cancer
Interventions: Other: cytology specimen collection procedure;   Other: laboratory biomarker analysis
Outcome Measures: Feasibility of NGS on metastatic solid tumor tissue, in terms of number of patients screened, FMI test attempted, FMI test successful, and FMI tests results released to physicians;   Feasibility of NGS result-based non-FDA-approved treatment plan, measured by reasons for ability or inability to receive an anti-Cancer agent;   Availability of recommended experimental regimens via clinical trials;   Proportion of patients who have one recommended therapy;   Proportion of patients who have multiple options recommended;   Presence of any oncogene or tumor suppressor gene mutations or amplifications identified by NGS on tumor tissue in each cohort
14 Recruiting Evaluate Risk/Benefit of Nab Paclitaxel in Combinaton With Gemcitabine and Carboplatin Compared to Gemcitabine and Carboplatin in Triple Negative Metastatic Breast Cancer
Conditions: Breast Tumor;   Breast Cancer;   Cancer of the Breast;   Estrogen Receptor- Negative Breast Cancer;   HER2- Negative Breast Cancer;   Progesterone Receptor- Negative Breast Cancer;   Recurrent Breast Cancer;   Stage IV Breast Cancer;   Triple-negative Breast Cancer;   Triple-negative Metastatic Breast Cancer;   Metastatic Breast Cancer
Interventions: Drug: nab-Paclitaxel 125 mg/m2 plus carboplatin AUC 2 in triple negative metastatic breast Cancer (TNMBC) subjects;   Drug: Carboplatin AUC 2;   Drug: gemcitabine 1000 mg
Outcome Measures: Progression Free Survival (PFS) for triple negative metastatic breast Cancer subjects (Phase 2);   Progression Free Survival (PFS) for triple negative metastatic breast Cancer subjects (Phase 3);   Investigator-determined Overall Response Rate (ORR) for triple negative metastatic breast Cancer subjects (Phase 2);   Percentage of triple negative metastatic breast Cancer subjects who initiated Cycle 6 (Phase 2);   Investigator determined Overall Survival (OS) for triple negative metastatic breast Cancer (TNMBC) subjects (Phase 2);   Safety for triple negative metastatic breast Cancer (TNMBC) subjects (Phase 2);   Independent blinded radiologists-determined Overall Response Rate (ORR) for triple negative metastatic breast Cancer (TNMBC) subjects (Phase 3);   Overall Survival (OS) for triple negative metastatic breast Cancer (TNMBC) subjects (Phase 3);   Compare disease control rate for triple negative metastatic breast Cancer (TNMBC) subjects (Phase 3);   Duration of Response for triple negative metastatic breast Cancer (TNMBC) subjects (Phase 3);   Safety of each treatment regimen for triple negative metastatic breast Cancer (TNMBC) subjects (Phase 3);   Investigator assessed Progression Free Survival (PFS)for triple negative metastatic breast Cancer (TNMBC) subjects (Phase 3)
15 Recruiting Tissue Procurement and Natural History Study of People With Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Extrapulmonary Small Cell Cancer, Pulmonary Neuroendocrine Tumors, and Thymic Epithelial Tumors
Conditions: Non-Small Cell Lung Cancer;   Small Cell Lung Cancer;   Extrapulmonary Small Cell Cancer;   Pulmonary Neuroendocrine Tumors;   Thymic Epithelial Tumors
Outcome Measures: Allow sample acquisition for use in the study of thoracic malignancies except mesothelioma.;   Follow the natural history of patients with thoracic malignancies.;   Conduct genomic, proteomic and immunological analyses on blood, tumor, body fluid and normal tissue in support of NIH translational trials to develop new therapeutic agents and novel treatment approaches as well as new prognostic and diagnostic ...
16 Recruiting Ohio Colorectal Cancer Prevention Initiative
Conditions: Lynch Syndrome;   Colorectal Cancer
Interventions: Genetic: LS tumor screening;   Genetic: Genetic testing;   Behavioral: Genetic Counseling;   Other: Biorepository;   Behavioral: Questionnaire
Outcome Measure: Determine the Incidence of Hereditary Cancer Syndromes among Newly Diagnosed Colorectal Cancer Patients
17 Recruiting Anxiety in Black Men With Prostate Cancer: Validation of the Memorial Anxiety Scale for Prostate Cancer in an Sample of Black Men
Condition: Prostate Cancer
Intervention: Behavioral: questionnaires of quality of life
Outcome Measures: To establish the psychometric properties of the Memorial Anxiety Scale for Prostate Cancer (MAX-PC) in Black men with prostate Cancer.;   To explore the prevalence of distress, anxiety, and depression in Black men with prostate Cancer.
18 Recruiting Computer Tools for Improving Early Diagnosis and Treatment in Healthy Volunteers or Patients With Pancreatic Cancer or Who Are At Risk For Pancreatic Cancer or Who Have a NonCancer Pancreatic Disorder
Condition: Pancreatic Cancer
Interventions: Other: medical chart review;   Other: questionnaire administration;   Other: study of socioeconomic and demographic variables;   Procedure: biopsy
Outcome Measures: Development of integrated Biomedical Computing Tools;   Development of the Pancreatic Cancer Collaborative Registry (PCCR) infrastructure as a repository for socio-demographic, environmental, clinical, and family history data;   Participation in the international pancreatic registry known as the PCCR by sharing information;   Collection and banking of excess biological materials (i.e., pancreatic tissue, tumor tissue ,and/or metastatic pancreatic Cancer tissue, and/or paraffin-embedded tissue), blood, and serum;   Establishment of an infrastructure with core data elements and standardized operating procedures for specimen collection, processing, and storage
19 Recruiting Changes in Breast Density and Breast Cancer Risk in Women With Breast Cancer and in Healthy Women
Condition: Breast Cancer
Interventions: Other: physiologic testing;   Other: screening questionnaire administration;   Procedure: breast imaging study;   Procedure: radiomammography;   Procedure: study of high risk factors
Outcome Measures: Within-individual mammographic density (MD) longitudinal change and breast Cancer risk;   Patterns of within-individual longitudinal change in MD;   Predictors of across-individual differences in MD change
20 Recruiting Germline Alterations of Tumor Susceptibility Genes in New York Cancer Patients
Conditions: Breast Cancer;   Bladder Cancer;   Kidney Cancer;   Colon Cancer;   Prostate Cancer;   Lung Cancer
Intervention: Genetic: PCR/PCR/LDR Strategy
Outcome Measures: To collect anonymized germline DNA from patients with breast, bladder, kidney, lung, colon, testicular, prostate, lymphoid, or head and neck Cancers, as well as patients with multiple primary Cancers, from select New York City ethnic groups.;   To analyze DNA samples from matched non-Cancer individuals of the same ethnic groups available as part of the AMDeC-sponsored New York Cancer Study.